Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study

AIMS/INTRODUCTION: It is unclear how changes in body composition induced by sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment correlate with metabolic profile changes. We aimed to clarify how metabolic profile changes correlate with body component changes, and if SGLT2 inhibitor treatment c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Takashi, Sugawara, Masahiro, Fukuda, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319483/
https://www.ncbi.nlm.nih.gov/pubmed/29660782
http://dx.doi.org/10.1111/jdi.12851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319483/
https://www.ncbi.nlm.nih.gov/pubmed/29660782
http://dx.doi.org/10.1111/jdi.12851

Ejemplares similares